全文获取类型
收费全文 | 13374篇 |
免费 | 602篇 |
国内免费 | 320篇 |
专业分类
耳鼻咽喉 | 144篇 |
儿科学 | 1629篇 |
妇产科学 | 882篇 |
基础医学 | 1397篇 |
口腔科学 | 293篇 |
临床医学 | 889篇 |
内科学 | 1616篇 |
皮肤病学 | 105篇 |
神经病学 | 671篇 |
特种医学 | 239篇 |
外科学 | 1507篇 |
综合类 | 1630篇 |
预防医学 | 1676篇 |
眼科学 | 90篇 |
药学 | 916篇 |
1篇 | |
中国医学 | 217篇 |
肿瘤学 | 394篇 |
出版年
2023年 | 92篇 |
2022年 | 264篇 |
2021年 | 338篇 |
2020年 | 278篇 |
2019年 | 290篇 |
2018年 | 268篇 |
2017年 | 321篇 |
2016年 | 393篇 |
2015年 | 407篇 |
2014年 | 803篇 |
2013年 | 945篇 |
2012年 | 731篇 |
2011年 | 862篇 |
2010年 | 705篇 |
2009年 | 666篇 |
2008年 | 688篇 |
2007年 | 708篇 |
2006年 | 646篇 |
2005年 | 537篇 |
2004年 | 475篇 |
2003年 | 377篇 |
2002年 | 319篇 |
2001年 | 289篇 |
2000年 | 292篇 |
1999年 | 211篇 |
1998年 | 204篇 |
1997年 | 181篇 |
1996年 | 164篇 |
1995年 | 167篇 |
1994年 | 175篇 |
1993年 | 149篇 |
1992年 | 100篇 |
1991年 | 133篇 |
1990年 | 125篇 |
1989年 | 104篇 |
1988年 | 98篇 |
1987年 | 79篇 |
1986年 | 79篇 |
1985年 | 90篇 |
1984年 | 85篇 |
1983年 | 40篇 |
1982年 | 54篇 |
1981年 | 54篇 |
1980年 | 44篇 |
1979年 | 39篇 |
1978年 | 30篇 |
1977年 | 29篇 |
1976年 | 33篇 |
1974年 | 22篇 |
1972年 | 23篇 |
排序方式: 共有10000条查询结果,搜索用时 515 毫秒
61.
目的:研究生长因子FGF在颅缝闭合中的调控作用.方法:以颅缝早闭动物模型(SD鼠)的颅缝为研究模型,采用细胞生物学技术、组织化学技术,研究颅缝闭合期间,生长因子bFGF作用下,细胞胶原及骨钙素分泌情况;观察生长因子bFGF,对分离培养的颅缝细胞增殖与代谢影响.结果:在大鼠颅缝分离培养细胞中,bFGF促进颅缝分离培养细胞分泌胶原、骨钙素,加快细胞增殖生长曲线平台期出现,并有效促进大鼠颅缝分离培养细胞S期增殖(p<0.05).结论:在体外器官培养中,bFGF能促进大鼠分离培养颅缝细胞的活性(p<0.05). 相似文献
62.
目的构建pEGFP-N1-GGF2质粒,观察其在大鼠脑组织中的表达。方法采用RT-PCR方法从人胚胎脑组织总RNA中扩增出人GGF2全长序列.并克隆到增强型绿色荧光蛋白(EGFP)基因真核表达载体pEGFP-N1上,构建pEGFP-N1-GGF2质粒.通过脂质体将pEGFP-NI-GGF2质粒转染大鼠脑组织.荧光显微镜下观察GGF2融合蛋白在大鼠脑内表达的时间和空间分布特征。结果成功构建了pEGFP-N1-GGF2表达载体,荧光显微镜观察可见,pEGFP-N1-GGF2表达载体转染6h大鼠脑内即可见GGF2融合蛋白表达.3d时融合蛋白表达最多,7d时表达量稍有下降但仍高,14d时表达量已明显下降。GGF2融合蛋白在脑内的表达以针道为中心向周围扩散.荧光信号可达皮层深部。结论脂质体介导的pEGFP-NI-GGF2质粒能够在大鼠脑内表达GGF2融合蛋白。 相似文献
63.
目的研究重组人生长激素(rhGH)对生长激素受体(GHR)不同表达状态裸鼠人胃癌移植瘤生长及血管内皮生长因子(VEGF)表达的影响。方法采用免疫细胞化学染色法筛选出GHR阳性和阴性表达的细胞株各1株,分别接种于24只裸鼠皮下。将两种细胞接种裸鼠均随机分为对照组(0.9%NaCl,0.2ml/d)、低剂量rhGH组(0.5U·kg^-1·d^-1,0.2ml/d)和高剂量rhGH组(2.5U·kg^-1·d^-1,0.2mL/d)3组,每组8只,各组均连续给药14d,观察并记录裸鼠体重和肿瘤体积变化;采用酶联免疫吸附法测定各组裸鼠血清VEGF含量,免疫组织化学方法检测胃癌组织中VEGF蛋白表达,RT-PCR方法检测胃癌组织VEGFmRNA水平变化。结果筛选出GHR阳性表达的人胃癌细胞株SGC-7901和阴性表达的MKN-45。对于GHR^+SGC-7901接种裸鼠,rhGH给药组皮下移植瘤体积较对照组增大(P〈0.05),且高剂量rhGH组促增长效应最为显著(P〈0.05),3组间体重差异无统计学意义(P〉0.05);高剂量rhGH组的血清VEGF浓度为(252.94±15.32)ng/L,明显高于对照组的(49.94±5.73)ng/L和低剂量rhGH组的(167.60±9.54)ng/L(P〈0.05);对照组VEGF表达为中度阳性,rhGH给药组呈强阳性;高剂量rhGH组肿瘤组织中VEGFmRNA相对表达量为0.6470±0.0447,明显高于对照组的0.3230±0.0258和低剂量rhGH组的0.4120±0.0351(P〈0.05)。对于GHR—MKN-45接种裸鼠,rhGH给药组体重明显大于对照组(P〈0.05);肿瘤体积大小、血清VEGF水平、肿瘤组织VEGF蛋白及mRNA表达,3组间差异均无统计学意义(P〉0.05)。结论rhGH能促进GHR阳性表达的SGC-7901移植瘤生长,并促进VEGF表达增高;对于GHR阴性的MKN-45移植瘤,则没有表现出明显的促肿瘤生长及促VEGF表达效应。GHR存在可能是rhGH影响VEGF分泌的关键靶点。 相似文献
64.
Nixie G. Raymond Johanna T. Dwyer Patricia Nevins Paul Kurtin 《Pediatric nephrology (Berlin, Germany)》1990,4(2):145-151
Children with mild to moderate renal insufficiency may be at an increased risk for developing glomerulosclerosis and subsequent renal failure. Low protein diets (LPD) have been shown to delay the progression of renal insufficiency in laboratory animals and may be of benefit in adult humans. The nutritional costs of a LPD in adults are reportedly minimal. We review the protein and caloric requirements of growing children and discuss the potential harmful effects and benefits of an LPD in this population. We also discuss dietary adherence and the difficulty of designing an LPD for children. We conclude that the protein content of a typical American diet can safely be reduced to, but not below, the recommended daily allowance for protein if diets are carefully planned, patients and their parents extensively counseled, and if dietary supplements are given to help meet the caloric and vitamin-mineral nutrient needs of growing children. In addition, ongoing nutritional assessment, counseling, and frequent monitoring of growth, diet and biochemical indicators of protein status are essential for maintaining the health of these children. 相似文献
65.
J. Marowska M. Kobylińska J. ?ukaszkiewicz A. Ta?ajko B. Rymkiewicz-Kluczyńska R.S. Lorenc 《BONE》1996,19(6):669-677
The aim of our study was to establish normal values of urinary pyridinoline (Pyr) and deoxypyridinoline (DPyr) excretion for children aged 3–18 years, examine the biological variability of the marker, and assess its clinical value for pediatric patients with growth hormone deficiency. Pyr and DPyr was measured in first void urine samples from 692 healthy subjects (340 boys, 352 girls) by high-performance liquid chromatography. At sampling, age, body height, and weight was recorded for all individuals. Short-term variability in crosslinks excretion was examined in four healthy children. The clinical value of the marker was studied in seven patients with growth hormone (GH) deficiency. In childhood, crosslinks excretion exceeded normal adult values by about fivefold and declined during puberty. In the age range of 13–18 years, gender-related differences in Pyr and DPyr levels were observed, presumably resulting from the earlier onset of puberty in girls. Urinary levels of Pyr and DPyr were highly correlated both in males and females. Pyr/DPyr ratio was significantly higher in adolescents than children, suggesting enhanced release of Pyr from extraosseous sources. In both genders, neither age nor anthropometric variables showed a linear effect on crosslinks excretion. The range of within-subject, short-term variability in urinary Pyr and DPyr was relatively high (CV: 6%–21%), indicating that single measurements of crosslinks excretion may not adequately reflect bone resorption rates in children. Pyr and DPyr levels were significantly lower in GH-deficient patients and normalized during human growth hormone (hGH) therapy. Significant correlations between growth velocity (GV) and crosslinks levels were found, but individual prediction of GV increment during hGH treatment may be inaccurate. Pyr/DPyr ratio was not related to GV. It is concluded that measurement of urinary Pyr and DPyr excretion in children may be a valuable tool to assess bone resorption rates in population-based studies. In individual patients, however, only qualitative evaluation of disease severity and response to treatment seems justified. 相似文献
66.
J. N. Laverri re J. L. Richard A. Morin N. Buisson A. Tixier-Vidal W. B. Huttner D. Gourdji 《Molecular and cellular endocrinology》1991,80(1-3):41-51
Secretogranin I (SgI; chromogranin B) belongs to a class of acidic tyrosine-sulfated secretory proteins believed to play a role in the secretory process of endocrine cells. Our aim here was to compare the levels of SgI mRNA to that of prolactin (PRL) and growth hormone (GH), using rat pituitary cell lines. As far as the constitutive expression is concerned, we found a positive correlation between SgI mRNA and PRL mRNA levels. However, the neuropeptide TRH (50 nM) inhibited the accumulation of SgI mRNA in GH3B6 cells whereas, as expected, it induced a rapid and sustained increase in PRL mRNA accumulation. By contrast, 17β-estradiol (1 nM) stimulated the accumulation of both SgI and PRL mRNAs, with the same EC50 (18–59 pM). Reciprocally, treatment with dexamethasone (100 nM) reduced the level of SgI and PRL mRNAs to 23% and 29% of control, respectively, but led to a 2.1-fold increase in the GH mRNA level. Altogether, the present work shows that SgI gene expression is subject to multiple hormonal regulations and occasionally parallels the regulation of the PRL gene but never that of the GH gene, under the conditions tested. 相似文献
67.
Summary The present study investigated the interactions of growth hormone (GH) and glucocorticoid on skeletal growth and bone structure in young mice. The purpose of this study was to examine the possible prevention by GH of the damage inflicted by dexamethasone (Dex) at sites of skeletal growth and ossification. Dex (1 mg/kg) with or without rat GH (rGH) or bovine GH (bGH), 1 mg/kg, was given for 4 weeks, from age 3–7 weeks, to female ICR mice. Tibiae, humerus, and vertebrae were analyzed morphometrically and biochemically. Growth, as determined by the mouse weight, tibial length, and humerus protein content was found to be compromised by dexamethasone. This was prevented by rGH or bGH. The epiphyseal growth plate width, trabecular bone volume, cortical bone width, mineral bone content, and alkaline and acid phosphatase activity were decreased by dexamethasone. These were prevented by rGH or by bGH. The findings of the present study suggest that in the mouse, GH can decrease or even avoid some of the pathological features in growing bones inflicted by high-dose glucocorticoid treatment. 相似文献
68.
S. Dietze D. Winkelmann R. Garve T. Blens J. Fanghnel P. Proff T. Gedrange S. Maile 《Annals of anatomy》2007,189(3):304-308
Numerous ritual acts involving the skull result in orofacial changes. The present study focuses on ritual acts of Brazilian Zoé Indians. A distinct deformation effect of the ritual act (wearing a lip-plug) on the morphology of the orofacial system is demonstrated and documented using jaw models. The studies show that the lip-plug significantly influences tooth position and jaw growth. While the maxilla displays palatal displacement of the lateral incisors and elevation of the palate, retraction occurs in the mandible depending upon plug size. Additionally, both the plug and the nutritional habits of the Indians induce marked abrasion of all teeth. Moreover, it is shown that the duration of lip-plug wear is an essential determinant of sustained orofacial changes. 相似文献
69.
S. W. J. LAMBERTS P. UITTERLINDEN T. VERLEUN 《European journal of clinical investigation》1987,17(4):354-359
Abstract. Several conflicting reports have been published with regard to the relationships between circulating growth hormone (GH), Somatomedin-C (SM-C) levels and clinical activity during different stages of therapy of acromegaly. We did not find a significant correlation between (fasting, post-prandial and mean 24-h) plasma GH and SM-C concentrations in twenty-two untreated acromegalic patients. There was a statistical significant correlation, however, if only the GH levels below 100 μg l-1 were considered (n=18 patients, P<0·01). The distribution of molecular forms of GH (‘little’, ‘big’ and ‘big-big’) did not differ between the four patients with GH levels above 100 μg l-1 and in four patients with levels between 40 μg l-1 and 80 μg l-1. Therefore, it is suggested that GH levels of 80–100 μg l-1 maximally activate Somatomedin-C production in man and that further increases in GH in general will not result in a further increase in SM-C generation. There was a significant correlation between GH and SM-C levels in forty-nine acromegalic patients after surgery and/or radiotherapy (P<0·001). In twenty-three of thirty-one patients with elevated SM-C levels the disease was subjectively still active, while this was the case in none of the patients with normal SM-C levels. In eight patients the disease was considered not to be clinically active any more, despite slightly increased SM-C levels. During long-term therapy of ten acromegalic patients for 16–108 weeks (mean 66±10) with 200–300 μg Sandostatin subcutaneously, clinical activity of the disease disappeared well before mean 24–h GH and SM-C levels reached the normal levels. There was a close correlation between mean 24-h GH and SM-C levels during Sandostatin therapy (P<0·001). ‘Clinical cure’ during this medical treatment was reached in five patients, as reflected by disappearance of subjective complaints, normalization of SM-C levels and 24-h mean GH levels of 2·8±0·2 μg l-1. Conclusions: (i) in untreated acromegaly, circulating GH and SM-C levels correlate well up to GH concentrations of 100 μg l-1. A further increase in GH does not result in a corresponding further increase in SM-C levels, suggesting a maximally activated production, without further GH-dependent capacity. (ii) Clinical ‘cure’ of acromegaly often occurs before normalization of the circulating SM-C levels. (iii) The measurement of plasma SM-C concentrations can be used well to adjust the dose and frequency of Sandostatin administration in acromegaly. This avoids the need of measuring extensive 24-h GH profiles. 相似文献
70.
不同分娩方式妇女放置三种IUD的术时评价 总被引:2,自引:1,他引:1
目的:研究不同分娩方式妇女放置三种新型含铜宫内节育器(CulUD)的术时评价。方法:将观察对象按经阴道和经剖宫产的不同分娩方式分为两组,每组均随机放置CyneFix IN IUD、MCu功能性IUD和TCu380A IUD,记录两组放置不同种IUD的扩宫情况、置器疼痛反应和置器时间。结果:放置GyneFix IN IUD和TCu380A IUD在不同分娩方式组中扩宫率、痛觉评分、置器时间无显著差异(P>0.05)。放置MCu功能性IUD在剖宫产分娩组扩宫率为92.5%,显著高于阴道分娩组的33.3%(P<0.05);痛觉评分为8.62±0.82分,显著高于阴道分娩组(P<0.01);置器时间为(9.62±3.15)min,较另两种IUD置器时间显著延长(P<0.05)。结论:GyneFix IN IUD和TCu380A IUD置器术时扩宫率低、费时少,疼痛反应轻,不受分娩方式影响。 相似文献